Skip to main content

Table 1 Patient characteristics at baseline (ITT population, n = 70)

From: A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer

  n (%)
Median age, years (range) 61 (39.5-73.8)
   35–49 years 10 (14.3%)
   50–64 years 36 (51.4%)
   ≥ 65 years 24 (34.3%)
Gender  
   Men 59 (84.3%)
   Women 11 (15.7%)
Median performance status (KPS) 90
   80% 25 (35.7%)
   90% 12 (17.1%)
   100% 33 (47.1%)
Histology  
   Squamous cell 31 (44.3%)
   Adenocarcinoma 23 (32.9%)
   Large cell Carcinoma 13 (18.6%)
   Giant cell carcinoma 3 (4.3%)
Staging  
   IIIA 20 (28.6%)
   IIIB 48 (68.6%)
   IV* 2 (2.9%)
Median delay between diagnosis and study entry, months (range) 1 (0.2-6.4)
  1. *Stage IV: Dubious at inclusion, was confirmed at following evaluations.